{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:52:07Z","timestamp":1781650327198,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Individuals with Type 2 diabetes (T2D) face a significantly elevated cardiovascular disease (CVD) risk. Among the various risk factors, dyslipidemia is strongly associated with CVD. Statins are the first-line treatment for patients at risk. Their ability to effectively reduce low-density lipoprotein (LDL) levels has made them a cornerstone in the prevention and management of CVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the pattern of statin prescription in T2D patients and follow its use as a primary and secondary prevention for CVD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>The study design was cross-sectional followed by a quasi-experimental pre\u2013post intervention. 210 T2D patients were recruited to evaluate the statin use regarding type, dose, adherence, and reason for use. After reporting the statin use pattern, all patients were subjected to one or more drug interventions: education about the importance of statin use, initiating statin in those who didn\u2019t use it before, changing the statin type and\/or dose, adding ezetimibe, and insisting on drug adherence. 3 months later, the statin use pattern was reevaluated to assess the percentage of patients who reached LDL and non high-density lipoprotein (non-HDL) targets according to 2023 European Society of Cardiology guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>210 T2D patients were recruited in the study with a mean age of 54.63\u2009\u00b1\u20099.77 years. 67.6% were females, and 49% were at very high CV risk. Only 90 (42.9%) were statin users with 12.2% adherence rate. Atorvastatin was the most prescribed statin. 55.3% (57 out of 103) of patients with a very high CV risk and 48.6% (17 out of 35) of patients with high CV risk were not on statin therapy. High-intensity statins were used by only 28.2% and 31.4% of very high and high CV risk patients, respectively. A few patients achieved the LDL and non-HDL targets on the first visit, even among statin users (6.6% and 7.7%, respectively). Despite the increased percentage of target achievement on second visit, only 64.3% of all included patients achieved LDL target, and 57.6% achieved non-HDL target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The majority of T2D patients were either non-statin or moderate-intensity statin users, despite their high and very high CV risk. High-intensity statins plus ezetimibe cannot always achieve LDL and non-HDL targets. Potential need for additional lipid-lowering therapies should be addressed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-026-02242-w","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:24:50Z","timestamp":1776090290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Statin prescription patterns among patients with type 2 diabetes mellitus for primary and secondary prevention of cardiovascular disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Asmaa Mohamed","family":"Abdelaal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ghonem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6525-5341","authenticated-orcid":false,"given":"Yasmin Atwa","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad S.","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Kyrillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"issue":"19","key":"2242_CR1","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1161\/CIRCULATIONAHA.118.037885","volume":"139","author":"N Sattar","year":"2019","unstructured":"Sattar N, Rawshani A, Franz\u00e9n S, Rawshani A, Svensson AM, Rosengren A, McGuire DK, Eliasson B, Gudbj\u00f6rnsdottir S. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks: findings from the Swedish National Diabetes Registry. Circulation. 2019;139(19):2228\u201337.","journal-title":"Circulation"},{"issue":"5","key":"2242_CR2","doi-asserted-by":"publisher","first-page":"101622","DOI":"10.1016\/j.cpcardiol.2023.101622","volume":"48","author":"O Gaidai","year":"2023","unstructured":"Gaidai O, Cao Y, Loginov S. Global cardiovascular diseases death rate prediction. Curr Probl Cardiol. 2023;48(5):101622.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"2242_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s42506-021-00096-9","volume":"96","author":"A Reda","year":"2021","unstructured":"Reda A, Ragy H, Saeed K, Alhussaini MA. A semi-systematic review on hypertension and dyslipidemia care in Egypt\u2014highlighting evidence gaps and recommendations for better patient outcomes. J Egypt Public Health Assoc. 2021;96(1):32.","journal-title":"J Egypt Public Health Assoc"},{"issue":"8","key":"2242_CR4","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1001\/jama.2022.12138","volume":"328","author":"R Chou","year":"2022","unstructured":"Chou R, Cantor A, Dana T, Wagner J, Ahmed AY, Fu R, Ferencik M. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022;328(8):754\u201371.","journal-title":"JAMA"},{"issue":"2","key":"2242_CR5","first-page":"182","volume":"43","author":"American Diabetes Association Primary Care Advisory Group","year":"2025","unstructured":"American Diabetes Association Primary Care Advisory Group. Standards of Care in Diabetes\u20142025 Abridged for Primary Care. Clin Diabetes 18 April. 2025;43(2):182.","journal-title":"Clin Diabetes 18 April"},{"issue":"1","key":"2242_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","volume":"120","author":"A Oesterle","year":"2017","unstructured":"Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circul Res. 2017;120(1):229\u201343.","journal-title":"Circul Res"},{"key":"2242_CR7","doi-asserted-by":"crossref","unstructured":"Mortensen MB, Falk E, Li D, Nasir K, Blaha MJ, Sandfort V, Rodriguez CJ, Ouyang P, Budoff M. Statin trials, cardiovascular events, and coronary artery calcification: implications for a trial-based approach to statin therapy in MESA. JACC: Cardiovasc Imaging. 2018;11(2 Part 1):221\u201330.","DOI":"10.1016\/j.jcmg.2017.01.029"},{"issue":"39","key":"2242_CR8","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Schuett K, Mueller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"key":"2242_CR9","doi-asserted-by":"crossref","unstructured":"Akbar M, Jha D, Ali H, Ahmad T. Non-HDL estimation methods: advancing cardiovascular disease prediction. Indian J Pharm Pract. 2023;16(4).","DOI":"10.5530\/ijopp.16.4.52"},{"issue":"1","key":"2242_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12933-021-01338-y","volume":"20","author":"ML Morieri","year":"2021","unstructured":"Morieri ML, Perrone V, Veronesi C, Degli Esposti L, Andretta M, Plebani M, Fadini GP, Vigili de Kreutzenberg S, Avogaro A. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets\u2019 attainment in subjects with and without type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):144.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"2242_CR11","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, Giovas P, Bray S, Kiru G, Murphy J, Banach M, De Servi S, Gaita D, Gouni-Berthold I. EU-Wi de Cross-Section al Obser v at ion al Study of Lipid-Modifying Therapy Use in Se c ondary and Pr i mary Care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u201389.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"2242_CR12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11883-012-0291-7","volume":"15","author":"P Maningat","year":"2013","unstructured":"Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291.","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"2242_CR13","doi-asserted-by":"publisher","first-page":"oeac071","DOI":"10.1093\/ehjopen\/oeac071","volume":"2","author":"M Banach","year":"2022","unstructured":"Banach M, Penson PE. Adherence to statin therapy: it seems we know everything, yet we do nothing. Eur heart J open. 2022;2(6):oeac071.","journal-title":"Eur heart J open"},{"key":"2242_CR14","doi-asserted-by":"crossref","unstructured":"Bideberi AT, Mutagaywa R. Statin prescription patterns and associated factors among patients with type 2 diabetes mellitus attending diabetic clinic at Muhimbili National Hospital, Dar es Salaam, Tanzania. Diabetes, metabolic syndrome and obesity: targets and therapy. 2022 Jan 1:633\u201346.","DOI":"10.2147\/DMSO.S347765"},{"issue":"3","key":"2242_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7326\/M22-2904","volume":"176","author":"SD Navaneethan","year":"2023","unstructured":"Navaneethan SD, Zoungas S, Caramori ML, Chan JC, Heerspink HJ, Hurst C, Liew A, Michos ED, Olowu WA, Sadusky T, Tandon N. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Ann Intern Med. 2023;176(3):381\u20137.","journal-title":"Ann Intern Med"},{"key":"2242_CR16","doi-asserted-by":"publisher","first-page":"1061628","DOI":"10.3389\/fcdhc.2023.1061628","volume":"4","author":"S Nigussie","year":"2023","unstructured":"Nigussie S, Demeke F. Prescribing patterns of statins and associated factors among type 2 diabetes mellitus patients attended at Jugol General Hospital in eastern Ethiopia: A cross-sectional study. Front Clin diabetes Healthc. 2023;4:1061628.","journal-title":"Front Clin diabetes Healthc"},{"key":"2242_CR17","unstructured":"Melaku T, Solomon Y, Chelkeba L. Statin utilization patterns among Type 2 diabetes mellitus patients with high cardiovascular disease risks in Ethiopia. J Pharm Care. 2018:44\u201351."},{"issue":"1","key":"2242_CR18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s13104-019-4423-9","volume":"12","author":"GT Demoz","year":"2019","unstructured":"Demoz GT, Wahdey S, Kasahun GG, Hagazy K, Kinfe DG, Tasew H, Bahrey D, Niriayo YL. Prescribing pattern of statins for primary prevention of cardiovascular diseases in patients with type 2 diabetes: insights from Ethiopia. BMC Res Notes. 2019;12(1):386.","journal-title":"BMC Res Notes"},{"issue":"1","key":"2242_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/jrms.JRMS_100_18","volume":"24","author":"MA Hammad","year":"2019","unstructured":"Hammad MA, Sulaiman SA, Aziz NA, Noor DA. Prescribing statins among patients with type 2 diabetes: The clinical gap between the guidelines and practice. J Res Med Sci. 2019;24(1):15.","journal-title":"J Res Med Sci"},{"key":"2242_CR20","unstructured":"Ismail HM, Shora HA, Al-Nozha O, Yamany HA, Al-Nozha F, Zaitone SA, Alahmdi H, Aljohani A, Almohammadi N, Abdallah AR. Pattern of Statin use in patients with diabetes mellitus type 2 for primary and secondary prevention of cardiovascular disease in Saudi Arabia. Afr J Diabetes Med. 2020;28(2)."},{"key":"2242_CR21","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA. Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082\u2013143.","DOI":"10.1161\/CIR.0000000000000625"},{"issue":"2","key":"2242_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40292-025-00705-0","volume":"32","author":"A Cesaro","year":"2025","unstructured":"Cesaro A, Acerbo V, Scialla F, Golia E, Concilio C, Scherillo G, De Michele G, de Sio V, Capolongo A, Di Donato L, Monaco MG. Discrepancies between physician-perceived and calculated cardiovascular risk in primary prevention: implications for LDL-C target achievement and appropriate lipid-lowering therapy. High Blood Press Cardiovasc Prev. 2025;32(2):199\u2013208.","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"2242_CR23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","volume":"285","author":"G De Backer","year":"2019","unstructured":"De Backer G, Jankowski P, Kotseva K, Mirrakhimov E, Reiner \u017d, Ryden L, Tokg\u00f6zo\u011flu L, Wood D, De Bacquer D, De Backer G, Jankowski P. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135\u201346.","journal-title":"Atherosclerosis"},{"issue":"3","key":"2242_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ehj.2013.05.003","volume":"65","author":"A El Etriby","year":"2013","unstructured":"El Etriby A, Bramlage P, El Nashar A, Brudi P, DYSIS Egypt Investigators. The DYSlipidemia International Study (DYSIS)-Egypt: a report on the prevalence of lipid abnormalities in Egyptian patients on chronic statin treatment. Egypt Heart J. 2013;65(3):223\u201332.","journal-title":"Egypt Heart J"},{"issue":"10","key":"2242_CR25","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.3390\/jpm14101044","volume":"14","author":"JP Henry","year":"2024","unstructured":"Henry JP, Gabriel L, Luchian ML, Higny J, Benoit M, Xha\u00ebt O, Blommaert D, Telbis AM, Robaye B, Guedes A, Demeure F. Evaluating the Efficacy of a Pre-Established Lipid-Lowering Algorithm in Managing Hypercholesterolemia in Patients at Very High Cardiovascular Risk. J personalized Med. 2024;14(10):1044.","journal-title":"J personalized Med"},{"issue":"1","key":"2242_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12902-020-0516-7","volume":"20","author":"JC Mwita","year":"2020","unstructured":"Mwita JC, Godman B, Esterhuizen TM. Statin prescription among patients with type 2 diabetes in Botswana: findings and implications. BMC Endocr disorders. 2020;20(1):36.","journal-title":"BMC Endocr disorders"},{"issue":"3","key":"2242_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00592-017-1089-4","volume":"55","author":"R Scicali","year":"2018","unstructured":"Scicali R, Di Pino A, Ferrara V, Urbano F, Piro S, Rabuazzo AM, Purrello F. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Acta Diabetol. 2018;55(3):209\u201318.","journal-title":"Acta Diabetol"},{"issue":"3","key":"2242_CR28","doi-asserted-by":"publisher","first-page":"908","DOI":"10.3390\/jcm14030908","volume":"14","author":"A Hafiz","year":"2025","unstructured":"Hafiz A, Aljohani S, Kutbi H, Fatani N, Alkhathran L, Alyaqub M, Alhamed MS, Alhaqbani AO, Alhadlaq AA, Alsalman MA, Al Yami MS. Statin Use and Major Adverse Cardiovascular Events Among Patients with Ischemic Heart Diseases: A Multi-Center Retrospective Study. J Clin Med. 2025;14(3):908.","journal-title":"J Clin Med"},{"key":"2242_CR29","doi-asserted-by":"crossref","unstructured":"Jyotsna FN, Ahmed A, Kumar K, Kaur P, Chaudhary MH, Kumar S, Khan E, Khanam B, Shah SU, Varrassi G, Khatri M. Exploring the complex connection between diabetes and cardiovascular disease: analyzing approaches to mitigate cardiovascular risk in patients with diabetes. Cureus. 2023;15(8).","DOI":"10.7759\/cureus.43882"},{"issue":"1\u20132","key":"2242_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40119-014-0031-x","volume":"3","author":"A Reda","year":"2014","unstructured":"Reda A, Abdel-Rehim AA, Etman A, Afifi OSA. Centralized Pan-Middle East Survey on the under-treatment of hypercholesterolemia: results from the CEPHEUS Study in Egypt. Cardiol Ther apy. 2014;3(1\u20132):27\u201340.","journal-title":"Cardiol Ther apy"},{"issue":"1","key":"2242_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40119-017-0089-3","volume":"6","author":"A Reda","year":"2017","unstructured":"Reda A, Etman A, Abdel-Rahim A, Farag N, Sanad O, Salamah S. Centralized Pan-Middle East survey on the under-treatment of hypercholesterolemia: results from the CEPHEUS II study in Egypt. Cardiol Therapy. 2017;6(1):105\u201320.","journal-title":"Cardiol Therapy"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02242-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02242-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02242-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:57:20Z","timestamp":1781647040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02242-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2242"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02242-w","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"23 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Mansoura Faculty of Medicine Institutional Research Board (Code number: MS.23.07.2490) which performed in compliance with the ethical guidelines outlined in the 1964 Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed written consent was obtained from each participant included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}